Your browser doesn't support javascript.
loading
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study.
Meyo, Manuela Tiako; Boudou-Rouquette, Pascaline; Arrondeau, Jennifer; Yu Chen, Jeanne Qiong; Hirsch, Laure; Neveux, Nathalie; Fabre, Elizabeth; Guidet, Caroline; Damotte, Diane; Wislez, Marie; Alexandre, Jérôme; Durand, Jean-Philippe; Ulmann, Guillaume; Goldwasser, François.
Afiliação
  • Meyo MT; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France. Electronic address: manuela.tiako@aphp.fr.
  • Boudou-Rouquette P; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
  • Arrondeau J; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
  • Yu Chen JQ; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
  • Hirsch L; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
  • Neveux N; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; Department of Medical Biology, Cochin Hospital, AP-HP, Paris, France.
  • Fabre E; Department of Thoracic Oncology, Georges Pompidou European Hospital, AP-HP, CARPEM, France; INSERM U970, Université Paris Cité, INSERM, PARCC, F-75015 Paris, France.
  • Guidet C; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
  • Damotte D; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; Paris Cité University, France; Department of Pathology, Cochin Hospital, APHP, Paris, France.
  • Wislez M; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; Paris Cité University, France; Department of Pneumology, Thoracic Oncology Unit, Institut du Cancer Paris Carpem, Cochin Hospital, APHP, Paris, France.
  • Alexandre J; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; Paris Cité University, France; Institut des Cordeliers, INSERM U1147, Paris, France.
  • Durand JP; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
  • Ulmann G; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; Department of Medical Biology, Cochin Hospital, AP-HP, Paris, France.
  • Goldwasser F; Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; Paris Cité University, France; Institut Cochin, INSERM U1016, Paris, France.
Clin Nutr ESPEN ; 64: 44-50, 2024 Sep 06.
Article em En | MEDLINE | ID: mdl-39244156
ABSTRACT
BACKGROUND &

AIMS:

We previously reported in the ELY prospective study that increased resting energy expenditure (REE) - so-called hypermetabolism - worsened tumor response, 6-month progression-free (PFS) and overall survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI). Here, we investigated the effect of caloric coverage on the sensitivity to ICI.

METHODS:

We retrospectively analysed a multicentric database of mNSCLC patients treated with ICI. All patients had a baseline nutritional assessment including REE measured with indirect calorimetry and a dietitian estimation of food intakes. Measured/theoretical REE ≥110% defined hypermetabolism. Intakes ≥90% of estimated needs defined caloric coverage. The primary endpoint was PFS. Secondary endpoints included response rate and OS.

RESULTS:

Among 162 patients, 84 (51.9%) were normometabolic, and 78 (48.1%) hypermetabolic. In hypermetabolic patients, 40 (51.3%) met their caloric needs (group A) while 38 (48.7%) did not (group B). Median PFS was 4.3 vs. 1.9 months in groups A and B, respectively (HR 0.49, 95%CI [0.31-0.80], p = 0.004). The PFS achieved in the group A and in normometabolic patients were similar (HR 0.99, 95%CI [0.65-1.51], p = 0.95). In multivariate analysis, caloric coverage was independently associated with improved PFS in hypermetabolic patients (HR 0.56, 95%CI [0.31-0.99], p = 0.048). Among hypermetabolic patients, the median OS was higher in the group A (HR 0.58, 95%CI [0.35-0.95], p = 0.03).

CONCLUSION:

Energy supply is a critical determinant of the sensitivity to ICI in NSCLC patients. A randomized study to evaluate the benefit of early nutritional intervention is warranted.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article